Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer

Mol Imaging Biol. 2011 Jun;13(3):577-582. doi: 10.1007/s11307-010-0363-4.

Abstract

Purpose: The aim of this study was to investigate the change of 3'-[¹⁸F]fluoro-3'-deoxy-L: -thymidine (¹⁸FLT) uptake in normal bone marrow (BM) after inevitable radiation.

Procedures: Twenty-one non-small cell lung cancer patients who received carbon ion radiotherapy (CIRT) were studied with ¹⁸FLT-positron emission tomography/computed tomography (PET/CT) at pre- and post-CIRT. Radiation dose was calculated by radiation planning. Irradiated BM was divided into three groups (<10% of maximum dose, 10-30%, and >30%).

Results: ¹⁸FLT uptake clearly decreased at >10% irradiated areas and mildly decreased at <10% areas. ¹⁸FLT uptake was lowest just after CIRT, somewhat increased at 3 months, and remained unchanged for more than 1 year. There was no significant difference between 10-30% and >30% areas.

Conclusion: ¹⁸FLT revealed that BM function decreased by small dose such as <4.2-4.4 GyE/1 fraction of CIRT and is eradicated by >4.2-4.4 GyE/1 fraction.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Bone Marrow / diagnostic imaging*
  • Bone Marrow / radiation effects*
  • Carbon / therapeutic use*
  • Cell Proliferation
  • Demography
  • Dideoxynucleosides / pharmacokinetics*
  • Female
  • Humans
  • Ions
  • Lumbar Vertebrae / diagnostic imaging
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy*
  • Male
  • Positron-Emission Tomography
  • Radiopharmaceuticals / pharmacokinetics*
  • Tomography, X-Ray Computed

Substances

  • Dideoxynucleosides
  • Ions
  • Radiopharmaceuticals
  • Carbon
  • alovudine